

Best Pharmaceuticals for Children Act



BPCA Framework to Enable Pediatric Drug Development

At the BPCA Stakeholders Meeting December 14-15, 2020, speakers shared updates on current work within the BPCA program and identified challenges in pediatric drug development and therapeutics. Breakout sessions were held on pediatric drug development issues relating to:

- Advancing Clinical Trials
- Biomarkers Research
- PK Modeling that Informs Dosing
- Pediatric-Friendly Formulations
- Pharmacoepidemiology
- Systems Pharmacology

Since the meeting, additional progress has been made towards the development of a generic framework to provide an overall structure to enable pediatric drug development studies. The goal is to develop--in collaboration with subject matter experts (SMEs) in pediatric care and research--an annotated, selective, curated, collection of resources that will assist drug developers, researchers and clinicians for topics before conducting pediatric drug development research. Work on the framework will continue throughout 2021.

Please join these discussions on the following dates and times. Please feel free to join discussions for more than one group if interested. To obtain the Zoom meeting information, please email bpca@infinityconferences.com and request the Zoom information for the group(s) of interest.

Assembly Topic	Recurring Calls	First Call
PK Modeling to Inform Dosing	3rd Thursday of the month at 11 AM EDT	3/18/2021
Pediatric-Friendly Formulations	3rd Friday of the month at 1 PM EDT	3/19/2021
Pharmacoepidemiology	4th Tuesday of the month at 1 PM EDT (<i>NOTE: a different call time will be selected for the April call</i>)	3/23/2021
Biomarkers /Developmental Pharmacodynamics	4th Wednesday of the month at 4 PM EDT	3/24/2021
Systems Pharmacology	4th Friday of the month at 1:00 PM EDT	3/26/2021
Advancing Clinical Trial Design	•Initial Call: March 30 at 12:00 PM EST •Subsequent Calls: 4th Monday at 2:00 PM EST	3/30/2021

Questions? Contact bpca@infinityconferences.com